Table 3.
The prevalence of precancer and cancer among patients with atypical glandular cells with and without concurrent squamous cell abnormalities according to AGC categories.
| Group | Squamous lesions | Glandular lesions | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Categorie | Total | HSIL+, No. (%) | p | SCC, No. (%) | p | AIS+/AEH+, No. (%) | p | AC, No. (%) | p | |
| AGC + Sq | AEM | 8 | 0 | 1.000 | 0 | NS | 3 (37.5%) | 0.011 | 3 (37.5%) | 0.012 |
| AEC | 13 | 1 (7.7%) | 0 | 0 | 0 | |||||
| AGC-NOS | 5 | 0 | 0 | 1 (20.0%) | 0 | |||||
| AGC-FN | 17 | 1 (5.9%) | 0 | 8 (47.1%) | 6 (35.3%) | |||||
| Total | 43 | 2 (4.7%) | 0 | 12 (27.9%) | 9 (20.9%) | |||||
| AGC-Alone | AEM | 179 | 1 (0.6%) | 0.002 | 0 | 0.002 | 18 (10.1%) | <0.0001 | 16 (8.9%) | <0.0001 |
| AEC | 210 | 6 (2.9%) | 1 (0.5%) | 15 (7.1%) | 4 (1.9%) | |||||
| AGC-NOS | 258 | 8 (3.1%) | 1 (0.4%) | 15 (5.8%) | 12 (4.7%) | |||||
| AGC-FN | 79 | 6 (7.6%) | 3 (3.8%) | 41 (51.9%) | 33 (41.8%) | |||||
| Total | 726 | 21 (2.9%) | 5 (0.7%) | 89 (12.3%) | 65 (9.0%) | |||||
| AGC | AEM | 187 | 1 (0.5%) | 0.001 | 0 | 0.004 | 21 (11.2%) | <0.0001 | 19 (10.2%) | <0.0001 |
| AEC | 223 | 7 (3.1%) | 1 (0.5%) | 15 (6.7%) | 4 (1.8%) | |||||
| AGC-NOS | 263 | 8 (3.0%) | 1 (0.4%) | 16 (6.1%) | 12 (4.6%) | |||||
| AGC-FN | 96 | 7 (7.3%) | 3 (3.1%) | 49 (51.0%) | 39 (40.6%) | |||||
| Total | 769 | 23 (3.0%) | 5 (0.7%) | 101 (13.1%) | 74 (9.6%) | |||||
AC, adenocarcinoma.; AEC: atypical endocervical cells; AEM: atypical endometrial cells; AEH, atypical endometrial hyperplasia; AGC, atypical glandular cell; AGC + Sq, atypical glandular cells with concurrent squamous cell abnormalities; AGC-alone, atypical glandular cells without concurrent squamous cell abnormalities; AGC-NOS, atypical glandular cells, not otherwise specified; AGC-FN, atypical glandular cells, favor neoplastic; AIS, cervical adenocarcinoma in situ; hrHPV, high risk human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; SCC, squamous cell carcinoma; NS, not significant.